Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Shenqi Maixintong is a traditional Chinese medicine (TCM) capsule formulation developed by the Guangzhou Integrated Traditional Chinese and Western Medicine Hospital. It is primarily investigated for the treatment of carotid atherosclerosis and the prevention of cardiovascular and cerebrovascular diseases. The drug's mechanism of action involves the regulation of endothelial function and the inhibition of inflammatory and immune responses, which collectively work to suppress the formation and progression of atherosclerotic plaques. As a 'Shenqi' formulation, it likely contains *Ginseng* and *Astragalus* as key components, aimed at tonifying 'Qi' and improving blood circulation to provide secondary prevention against major cardiovascular events.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Shenqi Maixintong.